Genexine, Inc. (095700.KQ)

KRW 5590.0

(-3.79%)

Total Debt Summary of Genexine, Inc.

Genexine, Inc.'s latest annual total debt in 2023 was 67.42 Billion KRW , down -19.81% from previous year.
Genexine, Inc.'s latest quarterly total debt in 2024 Q1 was 68.66 Billion KRW , up 1.84% from previous quarter.
Genexine, Inc. reported annual total debt of 84.08 Billion KRW in 2022, up 61.02% from previous year.
Genexine, Inc. reported annual total debt of 52.21 Billion KRW in 2021, up 92.3% from previous year.
Genexine, Inc. reported quarterly total debt of 70.84 Billion KRW for 2024 Q2, up 3.18% from previous quarter.
Genexine, Inc. reported quarterly total debt of 80.88 Billion KRW for 2023 Q3, up 7.98% from previous quarter.

Annual Total Debt Chart of Genexine, Inc. (2023 - 2012)

Historical Annual Total Debt of Genexine, Inc. (2023 - 2012)

Year	Total Debt	Total Debt Growth
2023	67.42 Billion KRW	-19.81%
2022	84.08 Billion KRW	61.02%
2021	52.21 Billion KRW	92.3%
2020	27.15 Billion KRW	-31.04%
2019	39.37 Billion KRW	13.77%
2018	34.61 Billion KRW	126.33%
2017	15.29 Billion KRW	-23.57%
2016	20 Billion KRW	566.95%
2015	3 Billion KRW	0.0%
2012	- KRW	0.0%

Year	Total Debt	Total Debt Growth
2024 Q1	68.66 Billion KRW	1.84%
2024 Q2	70.84 Billion KRW	3.18%
2023 Q3	80.88 Billion KRW	7.98%
2023 Q2	74.9 Billion KRW	0.57%
2023 Q1	74.47 Billion KRW	-11.42%
2023 FY	67.42 Billion KRW	-19.81%
2023 Q4	67.42 Billion KRW	-16.64%
2022 Q2	67.35 Billion KRW	16.8%
2022 Q1	57.66 Billion KRW	10.44%
2022 FY	84.08 Billion KRW	61.02%
2022 Q4	84.08 Billion KRW	8.1%
2022 Q3	77.78 Billion KRW	15.48%
2021 Q3	46.17 Billion KRW	29.3%
2021 Q4	52.21 Billion KRW	13.09%
2021 FY	52.21 Billion KRW	92.3%
2021 Q1	31.98 Billion KRW	18.53%
2021 Q2	35.7 Billion KRW	11.64%
2020 Q2	41.71 Billion KRW	3.23%
2020 FY	27.15 Billion KRW	-31.04%
2020 Q4	26.98 Billion KRW	34.15%
2020 Q3	20.11 Billion KRW	-51.78%
2020 Q1	40.41 Billion KRW	3.06%
2019 Q4	39.21 Billion KRW	0.0%
2019 FY	39.37 Billion KRW	13.77%
2018 FY	34.61 Billion KRW	126.33%
2017 FY	15.29 Billion KRW	-23.57%
2016 FY	20 Billion KRW	566.95%
2015 FY	3 Billion KRW	0.0%
2013 Q3	13.07 Billion KRW	0.0%
2012 FY	- KRW	0.0%

Peer Total Debt Comparison of Genexine, Inc.

Name	Total Debt	Total Debt Difference
HLB Co., Ltd.	62.7 Billion KRW	-7.53%
iNtRON Biotechnology, Inc.	402.9 Million KRW	-16635.067%
BINEX Co., Ltd.	53.5 Billion KRW	-26.015%
Bioneer Corporation	44.63 Billion KRW	-51.047%
Anterogen.Co.,Ltd.	9.74 Billion KRW	-592.242%
MEDIPOST Co., Ltd.	52.33 Billion KRW	-28.831%
CrystalGenomics, Inc.	32 Billion USD	-110.689%
Helixmith Co., Ltd	20.22 Billion KRW	-233.34%
Chabiotech Co.,Ltd.	449.63 Billion KRW	85.004%
Medy-Tox Inc.	82.83 Billion KRW	18.596%
Peptron, Inc.	9.13 Billion KRW	-638.282%
Amicogen, Inc.	149.59 Billion KRW	54.927%
HLB Therapeutics Co.,Ltd.	10.02 Billion KRW	-572.768%
LegoChem Biosciences, Inc.	12.64 Billion KRW	-433.277%
ALTEOGEN Inc.	83.76 Billion KRW	19.508%
PharmaResearch Co., Ltd.	34.3 Billion KRW	-96.542%
SillaJen, Inc.	9.69 Billion KRW	-595.368%
JETEMA, Co., Ltd.	130.49 Billion KRW	48.331%
OliX Pharmaceuticals,Inc	39.35 Billion KRW	-71.32%
Genomictree Inc.	1.83 Billion KRW	-3575.191%
MedPacto, Inc.	8.6 Billion KRW	-683.662%
D&D Pharmatech	8.13 Billion KRW	-728.924%
EASY BIO,Inc.	82.27 Billion KRW	18.05%
GI Innovation, Inc.	3.72 Billion KRW	-1712.153%